ASCO GI Conference Coverage
Filter News By:
Featured News
View all
More News
(Eisai) Jan 27, 2021 - Data will include a late-breaking oral presentation from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) (NCT02811861) (Abstract # 269) evaluating KEYTRUDA plus LENVIMA and LENVIMA plus everolimus versus...
(Medscape Medical News) Jan 25, 2021 - Combining an EGFR inhibitor with a pair of checkpoint inhibitors can produce 'promising' activity in certain patients with colorectal cancer, according to an investigator from a phase 2 trial.
(Yahoo! Finance) Jan 20, 2021 – RenovoRx today announced two research studies were presented at the 2021 ASCO Gastrointestinal Cancers Symposium that further advance the science of pancreatic cancer treatment.
(GSK) Jan 16, 2021 - GlaxoSmithKline plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid cancers being presented today at the 2021 American Society of...
(Evaluate Vantage) Jan 18, 2021 - Enhertu’s additional approval this morning for Her2-positive gastric cancer coincided with the Asco-GI conference, which featured a front-line gastric cancer study of Five Prime’s bemarituzumab as a...
(The Center For Biosimilars) Jan 18, 2021 - Investigators have demonstrated that initial uptake of the first bevacizumab biosimilar (Mvasi, Amgen) in the United States was strongest for patients receiving treatment for metastatic...
(Yahoo! Finance) Jan 17, 2021 - Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for...
(NASDAQ) Jan 18, 2021 - Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively.
(OBR) Jan 17, 2021 - Ivosidenib added nearly three months to the median overall survival of previously treated patients with advanced IDH1-mutated cholangiocarcinoma (CCA), compared with placebo, according to findings reported at the...
(OBR) Jan 17, 2021 - Preoperative neoadjuvant modified FOLFIRINOX is associated with favorable overall survival (OS) rates in patients with borderline resectable pancreatic cancer, relative to historical data. But combining this therapy...

OBR Tweets

Apr 16
Early Impressions of IMpower010: What Might This Mean for Immunotherapy in Early-Stage Non-Small Cell Lung Cancer?… https://t.co/MwVpuqeCFN

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat… https://t.co/0in19JpTFM

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20 https://t.co/hPGQ0EeLgx

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20 https://t.co/9XpyqMU0X3

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20 https://t.co/IWQOcPAupf

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj